It will be interesting to see the relative bromodomain inhibitor responses of MPN or post-MPN AML patients who have inactivating EZH2 mutations, or ASXL1 or SRSF2 mutations which antagonize PRC2/EZH2 function (57, 114). Here, ASXL1 is linked to myeloproliferative neoplasm.